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OBJECTIVES We analyzed the incidence of implantable cardioverter-defibrillator (ICD) therapy in
survivors of cardiac arrest (CA) in the U.S. from 1996 through 2001.
BACKGROUND Cardiac arrest is a class I indication for ICD therapy. The current patterns of ICD utilization
in survivors of CA have not been fully examined.
METHODS We searched a representative sample of all hospital discharges for patients admitted with the
primary diagnosis of CA who survived to hospital discharge. Patients with a concomitant
diagnosis of acute myocardial infarction or previous ICD in situ were excluded.
RESULTS From 1996 to 2001, 113,262 patients were admitted for CA. Of those, 63,745 (56.3%) did
not survive to hospital discharge. Of the remaining 49,517 patients, 30.7% received an ICD
before discharge, with a gradual increase in implantation rates from 1996 (23.6%) to 2001
(46.3%). Using logistic regression for the years 2000 and 2001, patients who were discharged
without an ICD were older (odds ratio [OR] 0.93 for every 10-year increase in age, p 
0.001), more likely to be African American (OR 0.19, p  0.001), and more likely to be
admitted to a smaller hospital (OR 2.24 for each additional 100 beds, p  0.001). These
predictors were independent of other co-morbid illnesses.
CONCLUSIONS Although they are increasing, the rates of ICD therapy after CA remain very low. There are
gross discrepancies by race. At a time when newer indications for ICD implantation are
emerging, efforts should be focused on identifying the causes of this underutilization and
discrepancies in survivors of CA. (J Am Coll Cardiol 2004;44:855–8) © 2004 by the
American College of Cardiology Foundationt
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hardiac arrests (CAs) claim the lives of an estimated
40,000 people each year in the U.S. (1). The most
ommon cause of CA is ventricular fibrillation (VF). Sur-
ival for out-of-hospital CA victims is abysmal and inversely
roportional to the time to defibrillation (2). The implant-
ble cardioverter-defibrillator (ICD) was developed to
horten the time to life-saving therapy from minutes to
econds. Survivors of VF arrest are at high risk of fatal
rrhythmia recurrence (3).
Several large, prospective trials have demonstrated the
uperiority of ICD over anti-arrhythmic therapy in second-
ry prevention of CA (4–6). On the basis of this evidence,
A in the absence of a reversible cause is now a class I
ndication for ICD therapy (7).
Despite its widespread acceptance, evidence suggests that
he ICD is underutilized in CA survivors in many Western
ations. Implantation rates vary widely between industrial-
zed countries, although rates of CA are similar (8–10).
lso, demographic factors pertaining to race (11), gender
12), and age (13) have been shown to affect the rates of
erformance of invasive cardiac procedures in CA survivors.
We analyzed a nationally representative data base to
valuate trends in ICD utilization among CA survivors in
From the *Cardiovascular Institute and the †Department of Biostatistics, Univer-
ity of Pittsburgh, Pittsburgh, Pennsylvania. Drs. Voigt and Saba contributed equally
o this paper.
Manuscript received March 15, 2004; revised manuscript received April 23, 2004,
dccepted May 3, 2004.he U.S. from 1996 through 2001. We also examined the
nfluence of such factors as age, race, gender, and hospital
ize on implantation rates in this population.
ETHODS
ata source. The National Hospital Discharge Survey
NHDS) collects data on 1% of all discharges from U.S.
onfederal hospitals. Public use files include demographic
ata, seven diagnostic codes from the International Classi-
cation of Diseases-Ninth Revision-Clinical Modification
ICD-9-CM), four procedural codes, dates of hospital
dmission and release, sources of payment, and disposition
t discharge. We collected these files from 1996 through
001.
iagnoses and procedures. The NHDS records from
996 to 2001 were reviewed, and cases with VF (ICD-
-CM code 427.41), ventricular flutter (code 427.42), or
A (code 427.5) as a primary discharge diagnosis were
elected. Patients with a previous defibrillator (codes 37.97,
7.98, and 37.99) or with a secondary diagnosis of acute
ransmural myocardial infarction (MI) (codes 410.11,
10.41, 410.51, and 410.61) were excluded. The procedure
f interest included implantation of a new defibrillator
codes 37.94, 37.95, and 37.96) in patients who survived to
ospital discharge.
Co-morbid conditions affecting surveyed patients wereefined by their ICD-9-CM codes from the secondary
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Defibrillators in Survivors of CA August 18, 2004:855–8iagnoses. Special attention was focused on major co-
orbidities that can affect survival, such as liver failure
codes 570, 572.2, and 573.3), renal failure (codes 580, 584,
85, and 39.95), heart failure (codes 458.0, 458.8, 458.9,
85.5, 785.51, 785.59, and 796.3), respiratory failure (codes
18.81, 518.82, 518.85, 786.09, 799.1, and 96.7), or neu-
ologic failure (codes 293, 348.1, 349.3, 780.01, 780.09, and
9.14), as well as severe metabolic (code 276.2) or hemato-
ogic (codes 286.2, 286.6, 286.9, and 287.3–5) conditions.
tatistical analysis. Univariate analysis was undertaken
sing one-way analysis of variance for continuous variables
nd the chi-square test for categorical variables. Multivariate
nalysis using a binary logistic regression test was performed
o determine the independent predictors of discharge to
ome without ICD therapy. Patients who did not specify
heir racial background were excluded from the calculation
f race-specific rates, but were included in all other calcu-
ations. A p value of 0.05 was considered statistically
ignificant.
ESULTS
review of discharges of over 212 million hospitalizations
n the U.S. from 1996 through 2001 identified 115,361
dmissions with a primary diagnosis of VF, ventricular
utter, or CA. Of these patients, 2,099 were excluded due
o concurrent acute MI or previous defibrillator implanta-
ion. Of this cohort of 113,262 patients, 63,745 (56.3%) did
ot survive to hospital discharge.
tilization of ICD therapy. Of the remaining 49,517
atients who survived to hospital discharge, 15,189 (30.7%)
eceived an ICD before discharge. Implantation rates in-
reased gradually and significantly (p  0.001) from 23.6%
n 1996 to 46.3% in 2001.
African Americans were significantly (p  0.001) less
ikely than Caucasians to receive an ICD after surviving an
pisode of CA, with 8.7% of blacks undergoing ICD
mplantation before hospital discharge, compared with
0.9% of whites (Fig. 1). This racial gap between white and
lack survivors of CA in the utilization of ICD therapy
emained apparent over the study period of 1996 to 2001,
ut seemed to be closing as more black patients were
eceiving an ICD (29.2% in 2001 vs. 7.7% in 1996). The
hange between 1996 and 2001 in the utilization of the
CD represents an increase of 2.8-fold (280%) in the black
Abbreviations and Acronyms
CA  cardiac arrest
ICD  implantable cardioverter-defibrillator
ICD-9-CM  International Classification of Disease-9th
Revision-Clinical Modification
MI  myocardial infarction
NHDS  National Hospital Discharge Survey
OR  odds ratio
VF  ventricular fibrillationompared with 78% in the white population. Because of fheir small sample size, patients of other racial backgrounds
uch as American Indians and Asians were not included in
his analysis. Of note, 20.6% of patients admitted with a
rimary diagnosis of CA did not specify their racial back-
round and were therefore also excluded from this analysis.
Between 1996 and 2001, women were more likely than
en to be discharged home without an ICD after surviving
A (Fig. 2). During the study period, 4,693 (23.6%) of
9,848 women and 10,496 (35.4%) of 29,669 males received
n ICD. Unlike racial disparities, gender differences were
ot persistently present throughout the study period and
isappeared by the year 2001, where the rates of ICD
mplantation were actually higher in women (61.8%) com-
ared with men (36.1%). The gender gap in the utilization
f ICDs was present across racial boundaries, except among
frican Americans (p  0.001 for whites, p  0.030 for
atients of other races, and p  NS for blacks when
omparing the rates of ICD implantation in women vs.
en). It is important to note that this gender discrepancy
eems to have disappeared in the more recent years of the
urvey.
Patients discharged from smaller compared with larger
ospitals were less likely to receive ICD therapy, with rates
f ICD therapy ranging from 0% in very small hospitals (6
o 99 beds) to 56% in large hospitals (500 beds). It is
orth noting that the 0% rate of ICD in survivors of CA
rom the smallest hospitals might reflect the fact that these
ospitals lack the ability to provide this service to their
atients. Of note, however, is the fact that patients trans-
igure 1. Percentage of patients admitted to the hospital with a primary
iagnosis of ventricular flutter, ventricular fibrillation, or cardiac arrest and
urviving to discharge, who received an implantable cardioverter-
efibrillator (ICD) stratified by race. Note the significantly lower utiliza-
ion rate in black patients (broken line) compared with white patients
solid line). In 2001, even though closing, the racial gap does not seem to
ave disappeared.erred to larger facilities to undergo ICD placement are
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August 18, 2004:855–8 Defibrillators in Survivors of CAurveyed when discharged from these larger facilities and are
ot included in the statistics of the smaller hospitals.
The frequencies of major co-morbid illnesses in the
urvivors of CA were also analyzed in the study population
nd compared across racial boundaries. Compared with
hite survivors of CA, black patients had a lower prevalence
f metabolic acidosis (0% vs. 2.2%) and cardiovascular
ailure (0% vs. 2.8%), but had a higher incidence of
espiratory failure (44% vs. 31%), renal failure (8.2% vs.
.2%), and neurologic failure (28% vs. 22%). There were no
ace differences in the frequencies of hepatic failure (0%) or
ematologic abnormalities (0.7%).
Using binary logistic regression analysis for the years
000 and 2001 (Table 1), independent predictors of not
eceiving an ICD after surviving a hospitalization for CA
ncluded older age (odds ratio [OR] 0.93 for every 10-year
ncrease in age, p  0.001), black race (OR 0.19, p 
igure 2. Percentage of patients admitted to the hospital with a primary
iagnosis of ventricular flutter, ventricular fibrillation, or cardiac arrest and
urviving to discharge, who received an implantable cardioverter-
efibrillator (ICD) stratified by gender. Note the lower rates of utilization
f the defibrillator in women (broken line) compared to men (solid line)
n the early years. In 2001, the ratio of men to women receiving a
efibrillator seems to have reversed, with more women receiving an ICD.
Table 1. Binary Logistic Regression Analysis S
a Defibrillator Among Survivors of Sudden Ca
2000 and 2001
p Value
Age (per 10-yr increase) 0.001
Gender (women vs. men) NS
Race (black vs. white) 0.001
Hospital size (per 100 beds) 0.001
Renal failure 0.001
Respiratory failure 0.001
Cardiovascular failure NSCI  confidence interval; NS  not significant; OR  odds ratio.001), and being admitted to a small hospital (OR 2.24 for
very 100-bed increase in hospital size, p  0.001). The
resence of renal or respiratory failure was also a risk factor
or not receiving an ICD after surviving CA.
ISCUSSION
he results of this study suggest that ICD therapy is being
nderutilized for secondary prevention of CA, a finding
onsistent with previously published data (10,14). Still, in
001, the majority of patients admitted with malignant
entricular arrhythmias did not receive ICD therapy before
ischarge.
There are multiple potential explanations for ICD un-
erutilization in this high-risk population. First, implant
ates are highly associated with economic factors (15),
ncluding health care budgets, hospital size and resources,
he availability of electrophysiologists, and possibly also
ith insurance coverage. Our analysis suggests that there is
direct relationship between hospital size and ICD implan-
ation rates, which may partially reflect the availability of
rocedures in the smaller hospitals. There may be a general
eluctance within the medical community to implant defi-
rillators in survivors of CA who have significant co-
orbidities and limited life-expectancy. Finally, health care
roviders’ perception of CA as a painless way of dying may
rovide a barrier to appropriate ICD utilization (16).
This study also demonstrates the powerful influence of
emographic factors on ICD implantation rates. We show
hat among CA survivors, women are less likely than men to
eceive an ICD, a finding consistent with previous studies
17). It is promising, however, to see that this gender gap is
losing in more recent years; in particular, in the year 2001,
higher percentage of women than men received an ICD
fter surviving CA.
Increasing age was also associated with lower defibrillator
mplantation rates. This apparent inequity can be partially
xplained by the limited life-expectancy, higher incidence of
o-morbid conditions, and increased reluctance to undergo
nvasive procedures in the elderly. This trend is concerning,
owever, for several reasons. First, the incidence of out-of-
ospital cardiac arrest is highest in elderly patients (18). In
ddition, economic analysis of a CA trial (19) suggested that
ing the Independent Predictors of Receiving
Death in the United States for the Years
OR
95% CI
Lower Upper
0.93 0.90 0.96
1.07 0.98 1.16
0.19 0.13 0.29
2.24 2.15 2.33
0.25 0.14 0.46
0.73 0.67 0.79
0.86 0.61 1.19how
rdiac.
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Defibrillators in Survivors of CA August 18, 2004:855–8lacing an ICD in patients age 70 years or older is associated
ith a lower cost for the ICD per year of life saved, as
ompared with a population younger than 70 years.
During the study period, blacks were over three times less
ikely than whites to receive ICD therapy for CA, even after
ccounting for other co-morbid conditions. One contribut-
ng factor may be a difference in rates of consent between
lacks and whites, which has been shown elsewhere (20,21).
atient preferences alone cannot fully account for the
ramatic disparities seen in our study. In the Cardiac Access
ongitudinal Study, blacks were less likely than whites to
ee a cardiologist regularly, follow up with a physician who
s board-certified, or be admitted to a facility with a
atheterization laboratory (22). Our findings are consistent
ith recent data showing racial disparity in percutaneous
oronary intervention and ICD utilization (22,23), which
learly deserve continuing investigation.
Our retrospective, observational study has several impor-
ant limitations. The NHDS data base lacks detailed clinical
nformation. The validity of the data depends on the
ppropriate use of ICD-9-CM codes at the time of hospital
ischarge. The definition of CA in our study relies totally on
he ICD-9-CM code entered into the NHDS data base.
here are no means to confirm the accuracy of the diagnosis
f VF (e.g., through review of electrocardiographic tracings
r other parts of the medical record). Also, co-morbid
llnesses, for example, have been shown to be underreported
n hospital discharge data (24). In our study, underrepre-
entation of acute MI as a secondary diagnosis could explain
ome of the apparent low ICD rates in survivors of CA.
everal important factors, such as patient refusal of recom-
ended therapy, cannot be measured. It is impossible to say
ith certainty if patients received defibrillator therapy in the
eeks or months after discharge.
This study suggests marked underutilization of ICD
herapy in survivors of CA in the U.S. There are alarming
isparities along race lines in the treatment of those at
ighest risk of CA. At a time when indications for ICD
herapy are expanding, efforts should be focused toward
dentifying the causes of these disparities.
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f Cardiac Electrophysiology, University of Pittsburgh Medical
enter, 200 Lothrop Street, B535 PUH, Pittsburgh, Pennsylvania
5213. E-mail: sabas@msx.upmc.edu.
EFERENCES
1. State-specific mortality from sudden cardiac death: United States,
1999. MMWR Morb Mortal Wkly Rep 2002;51:1236.
2. Nichol G, Detsky AS, Stiell IG, Or K, Wells G, Laupacis A.
Effectiveness of emergency medical services for victims of out-of-
hospital cardiac arrest: a meta-analysis. Ann Emerg Med 1996;27:
700–10.3. Goldstein S, Landis JR, Leighton R, et al. Predictive survival models
for resuscitated victims of out-of-hospital cardiac arrest with coronary
heart disease. Circulation 1985;71:873–80.
4. The Antiarrhythmic Versus Implantable Defibrillator (AVID) Inves-
tigators. A comparison of antiarrhythmic drug therapy with implant-
able defibrillators in patients resuscitated from near-fatal ventricular
arrhythmias. N Engl J Med 1997;337:1576–83.
5. Kuck K, Cappato R, Siebels J, Ruppel R. Randomized comparison of
antiarrhythmic drug therapy with implantable defibrillators in patients
resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg
(CASH). Circulation 2000;102:748–54.
6. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable
Defibrillator Study (CIDS): a randomized trial of the implantable
cardioverter defibrillator against amiodarone. Circulation 2000;101:
1297–302.
7. Gregoratos G, Cheitlin MD, Conill A, et al. Guidelines for implan-
tation of cardiac pacemakers and antiarrhythmia devices. Executive
summary: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines. Circulation
1998;97:1325–35.
8. Seidel K, Senges J. Geographic differences in implantable cardioverter
usage. J Cardiovasc Electrophysiol 2002;13:S100–5.
9. Hlatky MA, Saynina O, Geppert J, Garber AM, McClellan MB.
Utilization and outcomes of the implantable cardioverter defibrillator,
1987 to 1995. Am Heart J 2002;144:397–403.
0. Ruskin JN, Camm AJ, Zipes DP, Hallstrom AP, McGrory-Usset
ME. Implantable cardioverter defibrillator utilization based on dis-
charge diagnoses from Medicare and managed care patients. J Car-
diovasc Electrophysiol 2002;13:38–43.
1. Groeneveld PW, Heidenreich PA, Garber AM. Racial disparity in
cardiac procedures and mortality among long-term survivors of cardiac
arrest. Circulation 2003;108:286–91.
2. Pires L, Sethuraman B, Guduguntla VD, Todd KM, Yamasaki H,
Ravi S. Outcome of women versus men with ventricular tachy-
arrhythmias treated with the implanted cardioverter-defibrillator.
J Cardiovasc Electrophysiol 2002;13:563–8.
3. Quan KJ, Lee JH, Costantini O, et al. Favorable results of implantable
cardioverter-defibrillator implantation in patients older than 70 years.
Ann Thoracic Surg 1997;64:1713–7.
4. McDonald KM, Hlatky MA, Saynina O, Geppert J, Garber AM,
McClellan MB. Trends in hospital treatment of ventricular arrhyth-
mias among Medicare beneficiaries, 1985 to 1995. Am Heart J
2002;144:413–21.
5. Ovsyshcher IE, Furman S. Determinants of geographic variations in
pacemakers and implantable cardioverter defibrillator implantation
rates. Pacing Clin Electrophysiol 2003;26:474–8.
6. Seidl K, Senges J. Geographic differences in implantable cardioverter
defibrillator usage. J Cardiovasc Electrophysiol 2002;13:S100–5.
7. Giacomini MK. Gender and ethnic differences in hospital-based
procedure utilization in California. Arch Intern Med 1996;156:
1217–24.
8. DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med
2003;349:1836–47.
9. Sheldon R, O’Brien BJ, Blackhouse G, et al. Effect of clinical risk
stratification of cost-effectiveness of the implantable cardioverter-
defibrillator: the Canadian Implantable Defibrillator Study. Circula-
tion 2001;104:1622–6.
0. Whittle J, Conigliaro J, Good CB, Lofgren R. Racial differences in the
use of invasive cardiovascular procedures in the Department of
Veterans Affairs Medical System. N Engl J Med 1993;329:621–7.
1. Russo AM, Hafley GE, Lee KL, et al. Racial differences in outcome
in the Multicenter UnSustained Tachycardia Trial (MUSTT): a
comparison of whites versus blacks. Circulation 2003;108:67–72.
2. LaVeist TA, Arthur M, Morgan A, et al. The Cardiac Access
Longitudinal Study: a study of access to invasive cardiology among
African American and white patients. J Am Coll Cardiol 2003;41:
1159–66.
3. Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the
management of coronary artery disease. Am Heart J 2000;139:848–57.
4. Romano PS, Mark DH. Bias in the coding of hospital discharge data
and its implications for quality assessment. Med Care 1994;32:81–90.
